1-7 of 7
B. Lioure
Close
Sort by
Journal Articles

Donor Response to G-CSF Is the Best Predictive Factor of Extensive Chronic Graft-Versus-Host Disease after Non Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation.

N. Dhedin, MD, T. Prebet, MD, D. Rea, MD, PHD, M.L. Tanguy, M. Kuentz, MD, N. Piard, MD, F. Norol, MD, PHD, J.P. Jouet, MD, Ja Rubeil, MD, R. Tabrizi, MD, B. Rio, MD, B. Lioure, MD, P. Tiberghien, MD, PHD, J.H. Bourrhis, MD, A. Sirvent, MD, P. Bordigoni, MD, D. Blaise, MD, Mauricette Michallet, MD, PHD, J.P. Vernant, MD
Journal: Blood
Blood (2007) 110 (11): 2188.
https://doi.org/10.1182/blood.V110.11.2188.2188
Published: 2007
Journal Articles

Allogeneic Stem Cell Transplantation (SCT) with Non Myeloablative Conditioning Regimen (NST) Following Intensive Consolidation May Be Equivalent to Conventional alloSCT and Superior to autoSCT for Patients over 50 with Acute Myeloid Leukemia (AML) in 1 st CR: First Results of the AML 2001 Trial.

B. Lioure, J. Delaunay, D. Blaise, N. Milpied, P. Guardiola, J.Y. Cahn, B. Witz, E. Jourdan, L. Legros, E. Randriamalala, M. Ojeda, C. Himberlin, Michel Attal
Journal: Blood
Blood (2006) 108 (11): 319.
https://doi.org/10.1182/blood.V108.11.319.319
Published: 2006
Journal Articles

No Benefit of Adding High-Dose Melphalan (HDM) Suppported by Autologous Stem Cell Transplantation (SCT) over Treatment with Conventional Induction, HD ARAC Consolidation, and Auto SCT (Busulfan + HDM) for Acute Myelogenous Leukemia (AML) under 60: First Results of the Randomized AML 2001 Trial.

B. Lioure, A. Pigneux, C. Recher, F. Witz, T. Lamy, N. Fegueux, C.E. Bulabois, N. Ifrah, I. Luquet, D. Bouscary, N. Vey, M. Delain, J.O. Bay, P. Turlure, Jean-Luc Harousseau
Journal: Blood
Blood (2006) 108 (11): 608.
https://doi.org/10.1182/blood.V108.11.608.608
Published: 2006
Journal Articles

Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients with AL (Primary) Amyloidosis: Results of the French Multicentric Randomized Trial (MAG and IFM Intergroup).

A. Jaccard, P. Moreau, V. Leblond, X. Leleu, L. Benboubker, O. Hermine, C. Recher, M. Malphette, B. Lioure, B. Royer, B. Grosbois, J. Jaubert, P.M. Preux, M. Cogne, J.P. Fermand
Journal: Blood
Blood (2005) 106 (11): 421.
https://doi.org/10.1182/blood.V106.11.421.421
Published: 2005
Journal Articles

Blockade of p110delta Isoform Activity of Phosphoinositide 3-Kinase Inhibits Blast Cell Proliferation in Acute Myeloblastic Leukemia.

D. Bouscary, MD-PhD, V. Bardet, MD, P. Sujobert, MD, P. Cornillet-Lefebvre, MD, J. S. Hayflick, PhD, N. Prie, MD, F. Verdier, PhD, B. Vanhaesebroeck, PhD, O. Muller, F. Pesce, MD, N. Ifrah, MD, M. Hunault Berger, MD-PhD, C. Bertho, MD-PhD, G. Guillerm, MD, B. Villemagne, MD, B. Audhui, MD, E. Solary, MD-PhD, F. Witz, MD, J. L. Harousseau, MD, C. Himberlin, MD, T. Lamy, MD-PhD, B. Lioure, MD, M. C. Bene, MD, J. Y. Cahn, MD, F. Dreyfus, MD, P. Mayeux, PhD, C. Lacombe, MD-PhD
Journal: Blood
Blood (2004) 104 (11): 2522.
https://doi.org/10.1182/blood.V104.11.2522.2522
Published: 2004
Journal Articles

Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle

L Sutton, C Chastang, P Ribaud, JP Jouet, M Kuentz, M Attal, J Reiffers, JM Tigaud, B Rio, C Dauriac, M Legros, F Dreyfus, B Lioure, X Troussard, N Milpied, F Witz, P Oriol, JY Cahn, M Michallet, E Gluckman, N Ifrah, JL Pico, E Vilmer, V Leblond
Journal: Blood
Blood (1996) 88 (1): 358–365.
https://doi.org/10.1182/blood.V88.1.358.358
Published: 1996
Journal Articles

Molecular analysis of T-cell receptor V beta chains of human T-cell chronic lymphocytic leukemia does not show intraclonal variability: implications for immunotherapy

F Picard, T Martin, F Legras, B Lioure, JL Pasquali
Journal: Blood
Blood (1993) 82 (7): 2152–2156.
https://doi.org/10.1182/blood.V82.7.2152.2152
Published: 1993